Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of the proposed study is to determine the potential role of Ketamine as
an analgesic agent in pediatric sickle cell disease patients with refractory symptoms in
acute (VOC).